GlassScriptPhysician profile
Adrienne Gonzales
NPI 1013477801
$4,363.52
in general payments reported to CMS, 2019-2025
21 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $283 · 2023: $559 · 2024: $1,323 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,972.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $996.72 | 2024-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $878.56 | 2023-2025 | Biktarvy, Yeztugo |
| Abbvie INC. | $641.61 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $304.21 | 2024-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $291.15 | 2024-2025 | Rezzayo, Kimyrsa, Orbactiv |
| La Jolla Pharmaceutical Company | $232.74 | 2023 | Xerava, Xacduro |
| Astellas Pharma US INC | $158.35 | 2022 | |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| Novo Nordisk INC | $124.99 | 2022 | |
| Glaxosmithkline, LLC. | $107.82 | 2021 | |
| Ani Pharmaceuticals, INC. | $83.45 | 2024-2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $82.76 | 2024-2025 | |
| Insmed, INC. | $79.95 | 2024-2025 | Arikayce |
| Amgen INC. | $48.39 | 2024-2025 | Tezspire |
| Theratechnologies INC. | $48.12 | 2025 | Egrifta, Trogarzo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $33.64 | 2025 | Prolastin-C Liquid |
| Redhill Biopharma INC. | $28.85 | 2024 | Talicia |
| Verona Pharma, INC. | $28.07 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $26.72 | 2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $23.01 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $19.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.